Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole

Journal of Pediatrics

Volumn 149, Issue 3, 2006, Pages 416-420

  Kreher, Nerissa C ^a   Pescovitz, Ora Hirsch ^a   Delameter, Paul ^a   Tiulpakov, Anatoly ^a   Hochberg, Ze'ev ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BICALUTAMIDE; ESTRADIOL; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GONADOTROPIN; LEUPRORELIN; LUTEINIZING HORMONE; TESTOSTERONE;

ABSENCE OF SIDE EFFECTS; ACNE; ARTICLE; BONE AGE; BONE MATURATION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FAMILY HISTORY; GONADORELIN TEST; GROWTH RATE; HUMAN; INFORMED CONSENT; LABORATORY TEST; MALE; PRECOCIOUS PUBERTY; PRESCHOOL CHILD; PRIORITY JOURNAL; SEXUAL DEVELOPMENT; TESTIS; TESTIS SIZE; ULTRASOUND;

ANDROGEN ANTAGONISTS; ANILIDES; AROMATASE INHIBITORS; CHILD; CHILD, PRESCHOOL; HUMANS; MALE; MUTATION; NITRILES; PUBERTY, PRECOCIOUS; RECEPTORS, LH; TRIAZOLES;

EID: 33748155392     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2006.04.027     Document Type: Article

References (29)

1. Schedewie H.K., Reiter E.O., Beitins I.Z., Seyed S., Wooten V.D., Jimenez J.F., et al. Testicular Leydig cell hyperplasia as a cause of familial sexual precocity. J Clin Endocrinol Metab 52 (1981) 271-278
2. Rosenthal S.M., Grumbach M.M., and Kaplan S.L. Gonadotropin-independent familial sexual precocity with premature Leydig and germinal cell maturation (familial testotoxicosis): effects of a potent luteinizing hormone-releasing factor agonist and medroxyprogesterone acetate therapy in four cases. J Clin Endocrinol Metab 57 (1983) 571-579
3. Shenker A. Activating mutations of the lutropin choriogonadotropin receptor in precocious puberty. Receptors Channels 8 (2002) 3-18
4. Leschek E.W. Familial male-limited precocious puberty. Endocrinologist 14 (2004) 148-151
5. Janssen P.A., and Symoens J.E. Hepatic reactions during ketoconazole treatment. Am J Med 74 (1983) 80-85
6. Laue L., Chan W.Y., Hsueh A.J., Kudo M., Hsu S.Y., Wu S.M., et al. Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty. Proc Natl Acad Sci U S A 92 (1995) 1906-1910
7. Latronico A.C., Shinozaki H., Guerra Jr. G., Pereira M.A., Lemos Marini S.H., Baptista M.T., et al. Gonadotropin-independent precocious puberty due to luteinizing hormone receptor mutations in Brazilian boys: a novel constitutively activating mutation in the first transmembrane helix. J Clin Endocrinol Metab 85 (2000) 4799-4805
8. Bayley N., and Pinneau S.J. Tables for predicting adult height from skeletal age. J Pediatr 14 (1952) 432-441
9. Yano K Saji M., Hidaka A., Moriya N., Okuno A., Kohn L.D., and Cutler Jr. G.B. A new constitutively activating point mutation in the luteinizing hormone/choriogonadotropin receptor gene in cases of male-limited precocious puberty. J Clin Endocrinol Metab 80 (1995) 1162-1168
10. Laue L., Chan W.Y., Hsueh A.J., Kudo M., Hsu S.Y., Wu S.M., Blomberg L., and Cutler Jr. G.B. Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty. Proc Natl Acad Sci U S A 92 (1995) 1906-1910
11. Morishima A., Grumbach M.M., Simpson E.R., Fisher C., and Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80 (1995) 3689-3698
12. Smith E.P., Boyd J., Frank G.R., Takahashi H., Cohen R.M., Specker B., et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331 (1994) 1056-1061
13. Itoh K., Nakada T., Kubota Y., Suzuki H., Ishigooka M., and Izumi T. Testotoxicosis proved by immunohistochemical analysis and successfully treated with cyproterone acetate. Urol Int 57 (1996) 199-202
14. Wierman M.E., Beardsworth D.E., Mansfield M.J., Badger T.M., Crawford J.D., Crigler Jr. J.F., et al. Puberty without gonadotropins: a unique mechanism of sexual development. N Engl J Med 312 (1985) 65-72
15. Santen R.J., Van den Bossche H., Symoens J., Brugmans J., and DeCoster R. Site of action of low dose ketoconazole on androgen biosynthesis in men. J Clin Endocrinol Metab 57 (1983) 732-736
16. Holland F.J. Gonadotropin-independent precocious puberty. Endocrinol Metab Clin North Am 20 (1991) 191-210
17. Babovic-Vuksanovic D., Donaldson M.D., Gibson N.A., and Wallace A.M. Hazards of ketoconazole therapy in testotoxicosis. Acta Paediatr 83 (1994) 994-997
18. Leschek E.W., Jones J., Barnes K.M., Hill S.C., and Cutler Jr. G.B. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. J Clin Endocrinol Metab 84 (1999) 175-178
19. Fradet Y. Bicalutamide (Casodex) in the treatment of prostate cancer. Exp Rev Anticancer Ther 4 (2004) 37-48
20. Simard J., Singh S.M., and Labrie F. Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters. Urology 49 (1997) 580-586
21. Lonning P. Clinical pharmacokinetics of aromatase inhibitors and inactivators. Clin Pharmacokinet 42 (2003) 619-631
22. Kolvenbag G.J., and Blackledge G.R. Worldwide activity and safety of bicalutamide: a summary review. Urology 47 (1996) 70-79
23. Riepe F.G., Baus I., Wiest S., Krone N., Sippell W.G., and Partsch C.J. Treatment of pubertal gynecomastia with the specific aromatase inhibitor anastrozole. Horm Res 62 (2004) 113-118
24. Roth C., Freiberg C., Zappel H., and Albers N. Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol 15 (2002) 945-948
25. Mauras N., Welch S., Rini A., and Klein K.O. An open label 12-month pilot trial on the effects of the aromatase inhibitor anastrozole in growth hormone (GH)-treated GH deficient adolescent boys. J Pediatr Endocrinol 17 (2004) 1597-1606
26. Mauras N., O'Brien K.O., Klein K.O., and Hayes V. Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 85 (2000) 2370-2377
27. Hayes F.J., Seminara S.B., Decruz S., Boepple P.A., and Crowley Jr. W.F. Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback. J Clin Endocrinol Metab 85 (2000) 3027-3035
28. Muller J., Gondos B., Kosugi S., Mori T., and Shenker A. Severe testotoxicosis phenotype associated with Asp578-->Tyr mutation of the lutrophin/choriogonadotrophin receptor gene. J Med Genet 35 (1998) 340-341
29. Evans B.A., Bowen D.J., Smith P.J., Clayton P.E., and Gregory J.W. A new point mutation in the luteinising hormone receptor gene in familial and sporadic male limited precocious puberty: genotype does not always correlate with phenotype. J Med Genet 33 (1996) 143-147